NCT04244266

Observational Study in Bariatric Surgery

Observational Study of the Pharmacological Reversal of the Residual Neuromuscular Blockade in Bariatric Surgery

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 140 (actual)
• Sponsor: Poitiers University Hospital · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Accepted

Summary

Obesity in the world represents a growing share of the general population. At hospital, the management of these patients could be problematic especially when calculating the drug dosage. According to the French guidelines, neostigmine, a cholinesterase inhibitor, should be used to reverse a residual neuromuscular blockade at a dose of 0.4 mg/kg of total body weight in non-obese patients. In morbidly-obese patients, with the modification of the fat/lean mass ratio, the optimal dose of neostigmine is non-consensual. To calculate the dose of neostigmine, some anesthesiologists use the total body weight, others use the ideal body weight and others use the adjusted body weight. Due to this practice variability, It may be useful to observe the mean time to recovery of neuromuscular blockade and side effects after pharmacological reversal according to the dosage of neostigmine.

Conditions

• Obesity
• Neostigmine
• Residual Neuromuscular Blockade

Interventions

Type	Name	Description
OTHER	NO INTERVENTION, it is an observational study	No intervention

Timeline

• Start date: 2020-01-29
• Primary completion: 2023-06-14
• Completion: 2023-06-14
• First posted: 2020-01-28
• Last updated: 2023-07-06

Locations

1 site across 1 country: France